Targeted Therapy for a Cancer of Unknown Primary
Targeted therapy uses drugs or other substances to identify and attack cancer cells while doing little damage to normal cells. These therapies attack the cancer cells’ inner workings – the programming that makes them different from normal, healthy cells. Each type of targeted therapy works differently, but all alter the way a cancer cell grows, divides, repairs itself, or interacts with other cells.
One target on squamous cell cancers of the head and neck is called epidermal growth factor receptor (EGFR). Cells from many of these cancers have too many copies of EGFR, which helps them grow faster and become more resistant to radiation or chemotherapy (chemo). A drug called cetuximab (Erbitux®) blocks EGFR, and can help patients with squamous cell cancers of the head and neck area. It’s often used along with radiation or chemotherapy (chemo), but it can also be used by itself to treat people whose cancers no longer respond to chemo and who can’t take radiation.
A number of targeted therapy drugs are used to treat breast cancer, including trastuzumab (Herceptin®), pertuzumab (Perjeta®), lapatinib (Tykerb®), everolimus (Afinitor®), ado-trastuzumab emtansine (Kadcyla®, also known as TDM-1), and neratinib (Nerlynx®). For more information, see Targeted Therapy for Breast Cancer.
Other targeted therapy drugs are used for cancers that start in other areas, and may be helpful in some cases of cancer of unknown primary. For example, sunitinib (Sutent®) and everolimus (Afinitor®) are helpful in treating pancreatic neuroendocrine cancer, and may be used to treat well-differentiated neuroendocrine cancers of unknown primary.
More information about targeted therapy
To learn more about how targeted drugs are used to treat cancer, see Targeted Cancer Therapy.
To learn about some of the side effects listed here and how to manage them, see Managing Cancer-related Side Effects.
- Written by
- References
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.
Bochtler T, Löffler H, Krämer A. Diagnosis and management of metastatic neoplasms with unknown primary. Semin Diagn Pathol. 2017 Nov;26(pii). doi: 10.1053/j.semdp.2017.11.013. [Epub ahead of print].
Greco FA, Hainsworth JD. Carcinoma of Unknown Primary In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins 2015: 1719-1736.
Moran S, Martinez-Cardús A, Boussios S, Esteller M. Precision medicine based on epigenomics: The paradigm of carcinoma of unknown primary. Nat Rev Clin Oncol. 2017 Nov;14(11):682-694. doi: 10.1038/nrclinonc.2017.97.
National Cancer Institute. Physician Data Query (PDQ). Cancer of Unknown Primary Treatment. 07/25/2015. Accessed at: https://www.cancer.gov/types/unknown-primary/hp/unknown-primary-treatment-pdq on February 9, 2018.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Occult Primary. v.1.2018. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf on February 9, 2018.
Tomuleasa C, Zaharie F, Muresan MS, Pop L, Fekete Z, Dima D, Frinc I, Trifa A, Berce C, Jurj A, Berindan-Neagoe I, Zdrenghea M. How to diagnose and treat a cancer of unknown primary site. J Gastrointestin Liver Dis. 2017 Mar;26(1):69-79. doi: 10.15403/jgld.2014.1121.261.haz.
Varadhachary GR, Lenzi R, Raber MN, Abbruzzese JL. Carcinoma of Unknown Primary In: Neiderhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, PA. Elsevier: 2014:1792-1803.
Last Revised: March 9, 2018
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.